Aurora Investment Counsel Has $1.43 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Aurora Investment Counsel raised its stake in Royalty Pharma plc (NASDAQ:RPRX) by 1.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,441 shares of the biopharmaceutical company’s stock after purchasing an additional 512 shares during the period. Aurora Investment Counsel’s holdings in Royalty Pharma were worth $1,427,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of RPRX. Swedbank AB bought a new stake in Royalty Pharma in the 1st quarter valued at $251,461,000. New South Capital Management Inc. lifted its holdings in shares of Royalty Pharma by 60.7% during the 2nd quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company’s stock worth $61,943,000 after acquiring an additional 887,522 shares during the period. Dark Forest Capital Management LP lifted its holdings in shares of Royalty Pharma by 2,974.4% during the 2nd quarter. Dark Forest Capital Management LP now owns 338,675 shares of the biopharmaceutical company’s stock worth $8,931,000 after acquiring an additional 327,659 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Royalty Pharma by 69.0% during the 2nd quarter. AQR Capital Management LLC now owns 785,567 shares of the biopharmaceutical company’s stock worth $20,715,000 after acquiring an additional 320,606 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Royalty Pharma by 11,203.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 310,852 shares of the biopharmaceutical company’s stock worth $8,197,000 after acquiring an additional 308,102 shares during the period. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Trading Up 0.8 %

RPRX opened at $26.22 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $15.45 billion, a PE ratio of 13.59, a PEG ratio of 4.59 and a beta of 0.47. Royalty Pharma plc has a 1-year low of $25.10 and a 1-year high of $31.66. The firm has a 50-day moving average price of $27.35 and a two-hundred day moving average price of $27.41.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s payout ratio is presently 43.52%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of analyst reports. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup dropped their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group increased their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.